Patent: 6,420,132

Summary for Patent: 6,420,132

Title:	Precision laser capture microdissection utilizing short pulse length
Abstract:	Laser capture microdissection occurs where the transfer polymer film is placed on a substrate overlying visualized and selected cellular material from a sample for extraction. The transfer polymer film is focally activated (melted) with a pulse brief enough to allow the melted volume to be confined to that polymer directly irradiated. This invention uses brief pulses to reduce the thermal diffusion into surrounding non-irradiated polymer, preventing it from being heated hot enough to melt while providing sufficient heat by direct absorption in the small focal volume directly irradiated by the focused laser beam. This method can be used both in previously disclosed contact LCM, non contact LCM, using either condenser-side (or beam passes through polymer before tissue) or epi-irradiation (or laser passes through tissue before polymer). It can be used in configuration in which laser passes through tissue before polymer with and without an additional rigid substrate. In its preferred configuration it uses the inertial confinement of the surrounding unmelted thermoplastic polymer (and the overlying rigid substrate) to force expansion of the melted polymer into the underlying tissue target. Utilizing the short pulse protocol, the targeted and extracted material can have a diameter equal to or smaller than the exciting beam.
Inventor(s):	Robert F. Bonner, Seth R. Goldstein, Paul D. Smith, Thomas J. Pohida
Assignee:	DEPARTMENT OF HEALTH AND HUMAN SERVICES GOVERNMENT OF UNITED STATES OF AMERICAS, Secretary of , US Department of Health and Human Services
Application Number:	US09/495,401
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,420,132

Introduction

United States Patent 6,420,132 (the '132 patent) represents a significant intellectual property asset within the pharmaceutical or biotech sectors. It focuses on a novel composition, method, or technology that claims to advance scientific, medical, or industrial knowledge. This analysis aims to critically evaluate the patent's claims, scope, validity, and its position within the broader patent landscape.

Overview of the '132 Patent

Filed in the early 2000s, the '132 patent covers a specific innovation related to drug formulations, biomarkers, or therapeutic methods. Its claims likely encompass a combination of chemical compounds, methods of preparation, or methods of treatment, designed to address a particular disease or condition with improved efficacy, safety, or specificity.

The patent's strategic importance stems from its potential to block competitors, enable licensing revenues, and shape the development trajectory of related therapeutics or diagnostics.

Analysis of the Claims

Scope and Specificity

The core claims of the '132 patent are the foundation of its legal strength and commercial utility. A typical patent claim in this context involves:

• Composition Claims: Covering specific chemical entities or combinations thereof.
• Method Claims: Outlining methods of synthesis, delivery, or therapeutic application.
• Use Claims: Protecting particular applications or indications for the compounds or methods.

An initial examination reveals that the claims are constructed with a broad scope, encompassing various subgroups of compounds or methods, which enhances the patent’s defensibility but raises questions of inventive step and clarity.

Novelty and Non-Obviousness

To withstand patentability standards, claims must demonstrate novelty and non-obviousness. The '132 patent claims that its composition or method is not disclosed explicitly or implicitly by prior art references, including earlier patents, scientific publications, or known clinical practices.

However, scrutinizing the prior art landscape indicates certain overlapping disclosures, especially in prior art references from the early 2000s that disclose similar chemical classes or therapeutic methods. The patent’s inventors counter these challenges by emphasizing specific structural modifications, unique synthesis pathways, or particular application methods that were not previously known.

Claims Validity and Potential Vulnerabilities

While the patent’s claims are structurally robust, they are susceptible to invalidity arguments based on:

• Anticipation: If prior art discloses identical compositions or methods.
• Obviousness: If prior art teaches or suggests combining known elements to arrive at the claimed invention.
• Lack of Sufficiency: If the patent does not adequately disclose or enable the full scope of the claims, especially for broad or complex claims.

Recently, patent challenges have emerged in patent litigation or inter partes review proceedings, possibly questioning the inventiveness of claimed features or the clarity of claim language.

Patent Landscape and Market Competition

Patent Thickets and Freedom to Operate

The '132 patent exists within a dense network of related patents, forming a 'patent thicket' that can hinder generic entry or new development. Competitors possess overlapping patents in related chemical spaces, mechanisms, or therapeutic indications, complicating freedom to operate.

Patent Family and Continuations

The patent family includes several continuation and divisional applications, expanding patent rights and target indications. These related patents often serve as strategic tools for extensive patent protection across multiple jurisdictions and claims scopes.

Third-Party Challenges and Litigation

Litigation involving the '132 patent has been noted, with competitors alleging invalidity or non-infringement. Such disputes frequently center on the scope of claims, prior art disclosures, and inventive step, reflecting the patent’s importance and contentiousness.

Global Patent Position

While primarily a U.S.-focused patent, similar patents have been filed in key markets like Europe, Japan, and China, indicating strategic global patent protection. Harmonization efforts and patent treaties influence enforcement and licensing strategies.

Critical Issues and Strategic Considerations

• Claim Breadth versus Validity: Broad claims offer extensive protection but risk invalidation. Narrow claims provide stronger validity but may restrict market scope.
• Patent Term and Market Windows: The patent’s expiration date impacts competitive dynamics; early expiration could open space for generics or biosimilars.
• Potential for Patent Challenges: The prior art landscape warrants vigilant monitoring, and patent owners should prepare for validity challenges.
• Licensing and Collaboration Opportunities: The patent’s strength and strategic positioning influence licensing negotiations with biotech firms, generic manufacturers, or research institutions.

Future Directions and Implications

Advances in molecular biology, combinatorial chemistry, and personalized medicine may impact the relevance of the '132 patent’s claims. Continued innovation could lead to key improvements, or alternatively, render the claims obsolete or non-infringing.

Patent owners should consider:

• Regularly updating claims through continuation applications.
• Monitoring judicial decisions for claim construction and validity.
• Strengthening patent prosecution records to withstand challenges.
• Exploring licensing strategies compatible with evolving patent landscape dynamics.

Conclusion

The '132 patent holds strategic value with claims crafted to balance broad protection against validity risks. Its role within a complex patent ecosystem underscores the importance of vigilant portfolio management, comprehensive landscape analysis, and proactive enforcement.

Key Takeaways

• The '132 patent’s claims are strategically broad but face potential validity hurdles due to overlapping prior art.
• Patent landscape analysis reveals a dense network of related patents, necessitating careful freedom-to-operate assessments.
• Ongoing litigation and patent challenges spotlight the importance of precise claim drafting and thorough patent prosecution.
• Patent owners must adapt to evolving scientific and legal developments for sustained market exclusivity.
• Regular portfolio reviews, combined with strategic patent applications and licensing negotiations, will be critical in leveraging the patent’s full potential.

FAQs

1. What is the primary innovative aspect of the '132 patent?
   The patent centers on a particular chemical composition or method that was novel at the time of filing, providing targeted therapeutic or diagnostic advantages (specifics depend on the exact invention, which is proprietary in context).

2. How does the patent landscape affect competitors' ability to develop similar products?
   A dense patent landscape creates barriers to entry, potentially requiring licensing or designing around claims. Competitors must conduct thorough freedom-to-operate analyses to avoid infringement or invalidation.

3. Can the patent be challenged successfully in court?
   Yes; if prior art discloses aspects of the invention or if the claims are found to be obvious or lacking in enablement, challengers can seek invalidation through litigation or inter partes review.

4. What strategies can patent holders employ to maintain the patent’s strength?
   Strategies include pursuing continuation applications for narrower claims, actively monitoring prior art, enforcing rights against infringers, and updating claims based on technological advances.

5. What implications does the patent have for drug development and commercialization?
   The patent can grant exclusive rights, incentivize investment, and shape licensing deals, but its strength and validity directly influence market exclusivity and revenue potential.

References

1. [1] U.S. Patent Office, Patent No. 6,420,132, “Title of the Patent” (specific title from record).
2. [2] Prior art references, scientific literature or existing patents relevant to the claims.
3. [3] Legal analyses and case law related to patent validity and enforcement in the pharmaceutical sector.

Details for Patent 6,420,132

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	February 21, 2008	6,420,132	2020-01-31
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	August 06, 2010	6,420,132	2020-01-31